Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1All patients in the study will be treated with ocrelizumab[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
2Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab)[3] Ocrelizumab (Ocrelizumab),
Ofatumumab,
Rituximab		[3] Rituximab ,
Ocrelizumab (Ocrelizumab),
Ofatumumab 💬 		[1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
3Continued Ocrelizumab[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
4Interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab[12] Acetate,
Alemtuzumab,
Cladribine,
Dimethyl fumarate,
Fingolimod,
Glatiramer,
Natalizumab,
Ocrelizumab (Ocrelizumab),
Ofatumumab,
Ponesimod,
Rituximab,
Teriflunomide		[13] Cladribine ,
Alemtuzumab ,
Rituximab ,
Dimethyl fumarate ,
Fingolimod hydrochloride ,
Glatiramer acetate ,
Ocrelizumab (Ocrelizumab),
Natalizumab ,
Ofatumumab ,
Fingolimod ,
Teriflunomide ,
Ponesimod ,
Fingolimod lauryl sulfate 💬 		[26] DHODH,
HLA-A,
HLA-B,
HLA-C,
HLA-DMA,
HLA-DMB,
HLA-DOA,
HLA-DOB,
HLA-DPA1,
HLA-DPB1,
HLA-DQA1,
HLA-DQA2,
HLA-DQB1,
HLA-DRA,
HLA-DRB1,
HLA-DRB3,
HLA-DRB4,
HLA-DRB5,
HLA-E,
HLA-F,
HLA-G,
ITGA4,
KEAP1,
MS4A1,
RRM1,
S1PR1 💬 		[58] Allograft rejection, Antigen processing and presentation, Arrhythmogenic right ventricular cardiomyopathy, Asthma, Autoimmune thyroid disease, Cell adhesion molecule (CAM) interaction, Cellular senescence, Chemical carcinogenesis - reactive oxygen species, Cytoskeleton in muscle cells, Dilated cardiomyopathy, Drug metabolism - other enzymes, ECM-receptor interaction, Efferocytosis, Endocytosis, Epstein-Barr virus infection, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Glutathione metabolism, Graft-versus-host disease, Hematopoietic cell lineage, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IgSF CAM signaling, Inflammatory bowel disease, Influenza A, Integrin signaling, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Leukocyte transendothelial migration, Natural killer cell mediated cytotoxicity, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Pathways in cancer, Phagocytosis, Purine metabolism, Pyrimidine metabolism, Regulation of actin cytoskeleton, Rheumatoid arthritis, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Ubiquitin mediated proteolysis, Viral carcinogenesis, Viral myocarditis, Yersinia infection 💬[1] 13 💬
5Ocrelizumab[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[4] 11, 13, 46, 49 💬
6Ocrelizumab (CinnaGen, Iran)[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
7Ocrelizumab (EU)[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
8Ocrelizumab (Roche, Switzerland)[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
9Ocrelizumab (US)[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
10Ocrelizumab / rhuMAb 2H7[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 46 💬
11Ocrelizumab 300 mg[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
12Ocrelizumab 300mg[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
13Ocrelizumab 300mg /10ml[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
14Ocrelizumab 300mg/10 ml[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
15Ocrelizumab 300mg/10ml[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
16Ocrelizumab 500mg[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 46 💬
17Ocrelizumab 600 mg[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
18Ocrelizumab at home[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
19Ocrelizumab co-formulated with rHuPH20[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
20Ocrelizumab Dose 1[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
21Ocrelizumab Dose 2 and Dose 3[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
22Ocrelizumab Injection [Ocrevus][1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
23Ocrelizumab IV[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
24Ocrelizumab Reference Formulation[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
25Ocrelizumab SC[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
26Ocrelizumab Test Formulation[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
27Ocrelizumabu 200mg----[1] 46 💬
28Ocrelizumabu 50mg----[1] 46 💬
29OcrevusPharmaceutical Form: Concentrate for solution for infusionINN or Proposed INN: OcrelizumabCAS Number: 637334-45-3Current Sponsor code: RO4964913Other descriptive name: OCRELIZUMABConcentration unit: mg/ml milligram(s)/millilitreConcentration type: equalConcentration number: 30-Pharmaceutical form of the placebo: Concentrate for solution for infusionRoute of administration of the placebo: Intravenous useTrade Name: GilenyaPharmaceutical Form: Capsule, hardINN or Proposed INN: FingolimodCAS Number: 162359-55-9Current Sponsor code: RO7079904Other descriptive name: FINGOLIMODConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 0.5-Pharmaceutical form of the placebo: CapsuleRoute of administration of the placebo: Oral use----[1] 13 💬
30Other: Multiple Sclerosis patients who have been on Ocrelizumab will undergo cognitive and fatigue assessments[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
31Other: Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq[8] Alemtuzumab,
Cladribine,
Hyaluronidase,
Natalizumab,
Ocrelizumab (Ocrelizumab),
Ofatumumab,
Rituximab,
Ublituximab		[10] Cladribine ,
Alemtuzumab ,
Rituximab ,
Hyaluronidase ,
Hyaluronidase ,
Ocrelizumab (Ocrelizumab),
Hyaluronidase ,
Natalizumab ,
Ofatumumab ,
Ublituximab 💬 		[3] ITGA4,
MS4A1,
RRM1 💬 		[21] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecule (CAM) interaction, Cytoskeleton in muscle cells, Dilated cardiomyopathy, Drug metabolism - other enzymes, ECM-receptor interaction, Focal adhesion, Glutathione metabolism, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, IgSF CAM signaling, Integrin signaling, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Purine metabolism, Pyrimidine metabolism, Regulation of actin cytoskeleton, Yersinia infection 💬[1] 13 💬
32Other: Observation of Ocrelizumab as Treatment in RRMS Patients[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
33Other: Ocrelizumab[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
34Perfusion of treatment Ocrelizumab[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
35Short-course Ocrelizumab[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬